Search alternatives:
systemic decrease » systemic disease (Expand Search), systemic diseases (Expand Search)
mg decrease » nn decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
50 mg » 10 mg (Expand Search)
systemic decrease » systemic disease (Expand Search), systemic diseases (Expand Search)
mg decrease » nn decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
50 mg » 10 mg (Expand Search)
-
1
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
2
-
3
-
4
-
5
Brivanib decreases the transcription of growth factors and their receptors in carbon tetrachloride.
Published 2014Subjects: -
6
-
7
-
8
-
9
SLE decreases risk for hormonal cancers.
Published 2021“…An OR to the left of the solid line represents a reduction in risk. (a) Breast cancer incidence in female SLE cohort is significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). …”
-
10
-
11
-
12
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
-
13
-
14
-
15
-
16
IgG-mediated systemic anaphylaxis decreased in BasoDTR mice.
Published 2013“…<p>(A) BasoDTR mice (n = 4 per group) were treated once i.p. with 25 or 50 µg/kg of DT or PBS at 4 days prior to and were i.v. injected with 500 µg rat anti-FcγRII/III (2.4G2) antibodies in 200 µl PBS. …”
-
17
-
18
-
19
-
20